Abstract Hepatic encephalopathy that is associated with severe liver failure may compromise the blood-brain barrier (BBB) integrity. However, the effects of less severe liver diseases, in the absence of overt encephalopathy, on the BBB are not well understood. The goal of the current study was to investigate the effects of hepatic ischemia-reperfusion (IR) injury on the BBB tight junction permeability to small, hydrophilic molecules using the widely used [
Introduction
Acute liver failure is a serious, life-threatening condition that may result in hepatic encephalopathy, coma, and death (Bernal and Wendon 2013) . Although somewhat debatable (Butterworth 2013) , several investigators have reported an increased BBB permeability in hepatic encephalopathy and coma (Butterworth 2016; Cauli et al. 2011; Chastre et al. 2013; Chen et al. 2009; Chen et al. 2013; McMillin et al. 2015) . However, the effects of less severe hepatic diseases in the absence of overt encephalopathy or coma, such as hepatic ischemia-reperfusion (IR) injury, on the BBB permeability have not been well understood.
Our recent studies (Miah et al. 2014 ) demonstrated that hepatic IR injury increased the expression of P-glycoprotein (P-gp) at the BBB, resulting in a decrease in the apparent in vivo brain uptake clearance of the P-gp marker rhodamine 123. Additionally, an in vivo study using sodium fluorescein (FL) (Miah et al. 2015) , as a BBB tight junction permeability marker to small hydrophilic molecules, indicated that IR significantly increased the brain concentrations of the marker. However, the brain concentrations corrected for the free drug concentration in plasma was similar in both groups, suggesting no change in the permeability through the BBB tight junctions as a result of IR. Because FL might also pass the BBB through some transporters (Hawkins et al. 2007; Huai-Yun et al. 1998; Loscher and Potschka 2005) , the true effects of hepatic IR on the integrity of BBB tight junctions remain to be determined by using a marker that is not subject to BBB transporters and is devoid of confounding factors such as binding to plasma proteins and hepatic metabolism.
Radiolabeled [
14 C]sucrose is a small (342 Da), hydrophilic molecule with a very low permeability across the intact BBB, which has no known binding to blood or plasma proteins and no significant systemic metabolism. Further, no significant facilitative or active transport of sucrose in vivo has been demonstrated in mammals to date. Therefore, it has been one of the most widely used small molecules for quantitative determination of blood-brain barrier (BBB) integrity in many in vitro (Behrens et al. 2015; Kochi et al. 1999; Oppenheim et al. 2013; Paulson et al. 2006) , in situ brain perfusion (Bickel et al. 1996; Cannon et al. 2012; Hawkins et al. 2010; Huber et al. 2002; Lochhead et al. 2012; Ronaldson et al. 2009 ), and in vivo (Bickel et al. 1998; Chavarria et al. 2010; Ferguson and Woodbury 1969; Jin et al. 2013; Lo et al. 1987; Ohno et al. 1978; Preston et al. 1984; Preston and Haas 1986; Preston and Webster 2002; Smith et al. 1988; Stolp et al. 2005; Yin et al. 2008; Ziylan et al. 1983; Ziylan et al. 1984; Ziylan et al. 1988 ) studies. Very recently , we demonstrated that the apparent brain uptake clearance (K in ) of [ 14 C]sucrose in normal rats, estimated by quantitation of total radioactivity in the brain, was around 6-7 fold higher than that of stable isotope labeled [ 13 C]sucrose, which was quantitated using a specific LC-MS/MS method. Upon chromatographic fractionation of the brain samples of rats injected in vivo with [ 14 C]sucrose, several peaks, in addition to the intact sucrose, were identified. Although the possibility of a minor systemic metabolism could not be ruled out, the higher K in values for [ 14 C]sucrose were attributed, at least in part, to presence of small lipophilic impurities in the stock solution of [ 14 C]sucrose, which could easily penetrate BBB. Therefore, it was suggested that specific quantitation of the stable isotope ( 13 C) of sucrose is a more accurate alternative to the current widespread use of the radioactive sucrose as a BBB permeability marker.
The main objective of the current study was to investigate the effects of hepatic IR on the BBB permeability to sucrose using the specific [ ]sucrose substantially overestimates the absolute permeability of BBB to sucrose, it may still be a valid marker in studies of the effects of a disease state on the BBB permeability when its brain uptake clearance is compared in healthy and diseased conditions. Therefore, a secondary objective of the study was to test whether the use of [ 14 C]sucrose would affect the conclusion of such studies.
Materials and methods

Chemicals and reagents
We purchased [UL- 3 H-Labelled rat serum albumin (RSA) was prepared and chromatographically purified as described before (Bickel et al. 1998) . The precipitability by trichloroacetic acid of the purified 3 H-RSA peak was greater than 98%. LC-MS grade water (J.T. Baker) was purchased from Avantor Performance Materials, Inc. (Center Valley, PA, USA). Analytical grade ammonium hydroxide and LC-MS grade acetonitrile (ACN) were purchased from Fisher Scientific (Fair Lawn, NJ, USA). For anesthesia, ketamine and xylazine solutions were purchased from Lloyd Laboratories (Shenandoah, IA, USA). Heparin solution was purchased from APP Pharmaceuticals (Schaumburg, IL, USA). All other chemicals were analytical grade and obtained from commercial sources.
Animals
Adult, male Sprague-Dawley rats were purchased from Charles River laboratory (Wilmington, MA) and acclimated in single, ventilated cages with 12-h dark-light cycles in a temperature-and humidity-controlled room with free access to the food and water. All the animal procedures used in this study were approved by Texas Tech University Health Sciences Center's Institutional Animal Care and Use Committee and were consistent with the guidelines set by the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) . Animals were randomly assigned to two experimental groups of [
14 C] and [ 13 C]sucrose, which were further divided into two groups of sham surgery (Sham) and IR, resulting in a total of 4 groups (n = 5-7/group). The average ± SD of body weights (g) of animals were 306 ± 12 (Sham) and 298 ± 14 (IR) for the [ 
Hepatic ischemia-reperfusion (IR) injury model
To determine whether the use of [ 1 3 C]sucrose or [ 14 C]sucrose would affect the outcome of BBB permeability studies in a disease model, the BBB permeability to [ 13 C] and [ 14 C]sucrose was determined in different groups of rats subjected to hepatic IR or sham surgery (Sham), as described before (Miah et al. 2015) . Briefly, after an overnight fast, rats were anesthetized with ketamine: xylazine (80:8 mg/kg) via intramuscular injection. For the IR group, after opening the abdomen, the blood supply to the entire liver was occluded by placing a microvascular clamp on the portal triad. Complete obstruction of blood flow to the liver was confirmed by visual inspection of the liver color. After 20 min of total hepatic ischemia (Pringle maneuver), the liver was reperfused with blood by removing the clamp. Finally, 5 ml of normal saline (37°C) was added to the abdominal cavity to compensate for the loss of fluids during the surgery, and the muscle and skin layers were closed. During the entire procedure, the rat body temperature was maintained at 37°C by using a heating lamp and a heating plate attached to a rectal temperature control probe. Sham animals underwent only laparotomy under identical experimental conditions but without any interruption of the blood supply to the liver. Rats were allowed to recover for 8 h before dosing with the markers.
Dosing and sampling
After 8 h of reperfusion, rats were anesthetized with ketamine: xylazine at a dose of 80:4 mg/kg. Subsequently, a catheter was placed into the femoral artery for the collection of blood samples. For the [ 13 C]sucrose study, a single 10-mg/kg dose of the marker was administered as a bolus dose (via penile vein). For the [ 14 C]sucrose study, the bolus dosing solution contained 3 μCi (~6.5 μg/kg) of the marker plus 10 μCi of 3 H-RSA, as the vascular marker. Our recent report ) indicated that the dose-corrected plasma/blood disposition of both markers were similar despite significant differences between the absolute doses of the two markers. Serial blood samples (~0.2 ml) were then collected for 30 min, a portion was centrifuged for collection of plasma and another portion was used for measurement of blood concentrations. Each time after collection of blood samples, the catheter was filled with heparin (10 U/ml) to prevent blood clotting. To remove the residual blood from the brains of animals injected with [
13 C]sucrose, at the end of sampling a catheter was placed in the left ventricle, and the whole body was perfused with ice-cold saline at a rate of 25 ml/min for 5 min. Finally, brain was collected from both groups and snap frozen in cold iso-pentane. All samples were kept at -80°C until analysis.
LC-MS/MS analysis of [ 13 C]sucrose
Before analysis of [ 13 C]sucrose by LC-MS/MS, plasma and blood samples were diluted 100-and 50-fold, respectively, and brain samples were homogenized in water (1:9). The LC-MS/MS method is described in a recent publication . In brief, brain homogenates and diluted plasma and blood samples (20 μl) were subjected to protein precipitation by the addition of 180 μl of acetonitrile: water (80:20), which also contained IS. Chromatographic separation was then performed using an Acquity BEH amide column (50 mm х 3 mm, 1.7 μm) and an isocratic mobile phase of acetonitrile: water: ammonium hydroxide (72:28:0.1, v/v), run a flow rate 0.2 ml/min. Column temperature was maintained at 45°C, and autosampler was at room temperature. The retention time of sucrose was~2.5 min, and the total run time was 6 min. The MRM was monitored in negative mode, and the transitions for H] analysis, one hemisphere of the brain was cut into small pieces, and 0.2-0.3 g of the brain tissue was added to 2 ml of Solvable to digest the tissue. Additionally, 20 μl of blood and plasma samples were added to 2 ml of solvable. After 24 h at room temperature, 100 μl of hydrogen peroxide was added to each sample to remove any possible color quenching, 12 ml of scintillation fluid was added, and the samples were subjected to the scintillation counter.
Analysis of AST and ALT
Plasma AST and ALT levels were measured to confirm the IRinduced hepatic damage by a kit from TECO diagnostics (Anaheim, CA), according to the manufacturer's protocol.
Pharmacokinetic analysis
Apparent brain uptake clearance (K in ) values were estimated after a 30-min sampling period for both plasma (K in-plasma ) and blood (K in-blood ) AUC data (Gjedde 1981) : To allow comparison of data between the [ 13 C] and [ 14 C]sucrose, the mass of the markers in the blood and brain were corrected for the injected dose and expressed as percentage of injected dose (%ID).
Statistical analysis
Comparison of two means for the IR and Sham groups was carried out by an unpaired, two-tailed Student's t-test. For ALT and AST measurements, two-way ANOVA, followed by Bonferroni post-hoc analysis was used. A p value of <0.05 was considered significant. Data are presented as mean ± SD or individual values.
Results
Plasma concentrations of the hepatic IR injury markers are presented in Fig. 1 . As demonstrated in this figure, hepatic IR injury significantly increased the plasma levels of ALT (Fig. 1a) and AST (Fig. 1b) in the IR animals, as compared with their respective Sham groups. Comparison of ALT or AST values across the two sucrose marker groups showed no significant differences between the two marker groups for AST (Fig. 1b) . However, the ALT levels in the [ (Fig. 1a) . Table 1 . IR caused a significant increase in the blood and plasma concentrations (Fig. 2) (Fig. 3c and d) followed similar patterns, suggestive of multicompartment disposition. Additionally, for both markers, the plasma concentrations (Fig.  3a and c) were higher than the corresponding concentrations in blood (Fig. 3b and d) , which is in agreement with the lack of penetration of sucrose to the red blood cells. Further, the blood and plasma concentrations (Fig. 3) and AUC 0-30 values (Fig.  4) of both markers in the IR animals were significantly higher than those in the Sham animals.
The terminal brain concentrations of [ (Fig. 6c and d) , based on the plasma (Fig. 6a and c) or blood ( Fig. 6b and d (Fig. 6a and b) . However, blood K in values for [ 14 C]sucrose were significantly (p = 0.0163) higher in the IR animals, compared with the Sham group (Fig. 6d) . 
Discussion
In this study, we examined the effects of hepatic IR injury on the permeability of BBB tight junctions to sucrose using an animal model of Pringle maneuver (total hepatic ischemia) that is used clinically during liver surgery for trauma, resection of cancerous tissue, or liver transplantation. A significant increase in the plasma concentrations of the liver injury markers, ALT and AST, in both [ (Fig. 6) . Therefore, whereas the [ 13 C]sucrose data do not suggest any changes in the BBB permeability to sucrose as a result of hepatic IR, the opposite is true based on the K in-blood values of [ 14 C]sucrose (Fig. 6) . Accurate measurement of brain concentrations of BBB markers with low permeability requires removal of the blood content of brain by perfusion or the use of a vascular marker to eliminate the contribution of brain blood to the total brain concentrations of the marker. Consequently, [ 14 C]sucrose is frequently used along with radioactive albumin as a vascular marker, a method that was also used in our studies. For the [ 13 C]sucrose, we chose to remove the brain blood by perfusion before collection of brain, in order to avoid the use of radioactive vascular markers. It may be argued that the differences between the two methods might be due to residual blood after the brain perfusion in the [ ]sucrose group, which is opposite of our observations (Fig. 6) .
The injection of RSA in the [ 14 C]sucrose group allowed us to estimate the volumes of brain plasma and blood, which were 8.99 and 16.6 μl/g, respectively, in the Sham animals (Table 1) , predicting a cerebral hematocrit of 0.46 in this group. These values are in agreement with the cerebral blood volume of 25.1 μl/g, measured by the summation of red blood cell volume ( 99m Tc-labelled red blood cells) and plasma volume ([ 14 C]dextran), and a hematocrit of 0.43 in control rats (Todd et al. 1992) . The estimated hematocrit in the brain blood (0.46) of our Sham animals is also close to the estimated hematocrit in the systemic blood (0.47) in the same group, with the latter obtained from the RSA blood and plasma AUC 0-30 values (Table 1 ). The V blood and V plasma values for the IR animals were not significantly different from those in the Sham animals ( Table 1 ), suggesting that our IR model does not affect the cerebral blood or plasma volumes.
The lack of a significant effect of a 20-min Pringle maneuver plus 8 h of reperfusion on the [
13 C]sucrose K in (Fig.  6a and b ) is in agreement with our recent study using sodium fluorescein (FL) as a BBB permeability marker in the same disease model (Miah et al. 2015) . Similar to sucrose, FL is a small, hydrophilic, low MW (374 Da) marker, which minimally crosses the intact BBB. However, the use of FL is subject to some inherent confounding problems, including disease state-induced potential changes in 
